期刊文献+

Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy 被引量:1

Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy
下载PDF
导出
摘要 The role of histone modifications in the development and progression of cancer remains unclear. Here,we gave an investigation of the relationship between the various histone modifications and the risk prediction of the biochemical recurrence after radical prostatectomy (RP). Histone 3 lysine 4 dimethylation (H3K4diMe),trimethylation (H3K4triMe),lysine 36 trimethylation (H3K36triMe),histone 4 lysine 20 trimethylation (H4K20triMe)and acetylation of histome 3 lysine 9 (H3K9Ac) were evaluated using immnuohistochemistry coupled with the tissue microarray technique in 169 primary prostatectomy tissue samples. Recursive partitioning analysis (RPA) was used to analyze the data. Through global histone modification analysis in patients who underwent radical prostatectomy,we found that H3K4triMe can predict the risk of the biochemical recurrence for the low grade prostate cancer (Gleason score≤6) after RP. In the case of high grade prostate cancer (Gleason score≥7),H4K20triMe and H3K9Ac accompanying with the pre-operation prostate-specific antigen (PSA) level could also predict the risk of the biochemical recurrence after RP. In combination with the Gieason score and pre-operation PSA level,the acetylation and methylation of histones H3 and H4 can predict the biochemical recurrence of the prostate cancer following RP. The role of histone modifications in the development and progression of cancer remains unclear. Here,we gave an investigation of the relationship between the various histone modifications and the risk prediction of the biochemical recurrence after radical prostatectomy (RP). Histone 3 lysine 4 dimethylation (H3K4diMe),trimethylation (H3K4triMe),lysine 36 trimethylation (H3K36triMe),histone 4 lysine 20 trimethylation (H4K20triMe)and acetylation of histome 3 lysine 9 (H3K9Ac) were evaluated using immnuohistochemistry coupled with the tissue microarray technique in 169 primary prostatectomy tissue samples. Recursive partitioning analysis (RPA) was used to analyze the data. Through global histone modification analysis in patients who underwent radical prostatectomy,we found that H3K4triMe can predict the risk of the biochemical recurrence for the low grade prostate cancer (Gleason score≤6) after RP. In the case of high grade prostate cancer (Gleason score≥7),H4K20triMe and H3K9Ac accompanying with the pre-operation prostate-specific antigen (PSA) level could also predict the risk of the biochemical recurrence after RP. In combination with the Gieason score and pre-operation PSA level,the acetylation and methylation of histones H3 and H4 can predict the biochemical recurrence of the prostate cancer following RP.
机构地区 Department of Urology
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2010年第2期171-179,共9页 亚洲男性学杂志(英文版)
关键词 biochemical recurrence histone modification IMMUNOHISTOCHEMISTRY prostate cancer radical prostatectomy tissue microarray biochemical recurrence,histone modification,immunohistochemistry,prostate cancer,radical prostatectomy,tissue microarray
  • 相关文献

参考文献39

  • 1Han M,Partin AW,Piantadosi S,Epstein JI,Walsh PC.Era specific biochemical recurrence-flee survival following radical prostatectomy for clinically localized prostate cancer.J Urol 2001;166:416-9.
  • 2Bott SR.Management of recurrent disease after radical prostatectomy.Prostate Cancer Prostatic Dis 2004;7:211-6.
  • 3Brenner H.Long-term survival rates of cancer patients achieved by the end of the 20th century:a period analysis.Lancet 2002;360:1131-5.
  • 4Molitiemo J,Evans A,Mohler JL,Wallen E,Moore D,et al.Characterization of biochemical recurrence after radical prostatectomy.Urol Int 2006;77:130-4.
  • 5Lapointe J,Li C,Higgins JP,van de Rijn M,Bair E,et al.Gene expression profiling identifies clinically relevant subtypes of prostate cancer.PNAS 2004;101:811-6.
  • 6Kurdistani SK.Historic modifications as markers of cancer prognosis:a cellular view.Br J Cancer 2007;97:1-5.
  • 7Lund AH,Lohuizen MV.Epigenetics and cancer.Genes Dev 2004;18:2315-35.
  • 8Ducass M,Brown MA.Epigenetic aberrations and cancer.Mol Cancer 2006;5:60.
  • 9Kuendgen A,Lübbert M.Current status of epigenetic treatment in myeiodysplastic syndromes.Ann Hematol 2008;87:601-11.
  • 10Feinberg AP,Tycko B.The history of cancer epigenetics.Nat Rev Cancer 2004;4:143-53.

同被引文献1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部